

For the following indication, MINJUVI™ has been approved *with conditions* (NOC/c). This means it has passed Health Canada's review and can be bought and sold in Canada, but the manufacturer has agreed to complete more studies to make sure the drug works the way it should. For more information, talk to your healthcare professional.

MINJUVI™ (tafasitamab) is indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, who are not eligible for autologous stem cell transplant (ASCT).

I'M ON A

MISSION
WITH "MINJUVI"™

YOUR GUIDE TO TREATMENT WITH MINJUVI™

DRAFT



MINJUVI™
tafasitamab for injection
200 mg/vial

Information you'll find in this booklet

What is DLBCL? X

How does MINJUVI™ work? X

What will my treatment schedule be like?..... X

What are the possible side effects of treatment? X

Your MINJUVI™ treatment tracker X

Your personalized discussion guide X

The Incyte Solutions™ Support Program X

Tips for caregivers and loved ones X

Frequently asked questions (FAQ) X

Glossary X

Taking the next step in your DLBCL journey

Your doctor has prescribed treatment with MINJUVI™, which can be used to treat adult patients who have had their DLBCL return after other treatments or when other treatments did not work.

This booklet was designed to help you navigate the next phase of your journey with DLBCL. Use this as a guide to help you understand how MINJUVI™ works, how you can track your treatment, and more.



Your healthcare team contact information

Fill out the information below to help you stay in contact with your healthcare team.

Hospital (or clinic) name _____

Address _____

Email _____

Phone _____

Doctor's name _____

Email _____

Phone _____

Nurse's name _____


Email _____

Phone _____

Other contact(s) _____

What is diffuse large B-cell lymphoma (DLBCL)?

DLBCL is the **most common type of non-Hodgkin lymphoma (NHL)** and is usually fast-growing. DLBCL specifically affects **mature B cells**, a type of white blood cell.



When DLBCL returns or stops responding to treatment

First-line treatment is the first treatment or series of treatments received.

Second-line (or subsequent) treatment is used when DLBCL has relapsed (returned) or become refractory (stopped responding) during a previous treatment. These treatment options are based on whether a blood stem cell transplant is part of the treatment plan.

One example of a blood stem cell transplant is an **autologous stem cell transplant (ASCT)**, meaning your own blood stem cells are collected and later given back to you to help your body fight the cancer.



When DLBCL relapses or becomes refractory, doctors decide whether a transplant is an option based on many factors, such as:

- Any illnesses other than cancer
- How well your organs are working
- What you want
- Other relevant medical history

After first-line treatment, your doctor uses a variety of information to carefully decide which option is best for you.

I'M ON A
MISSION
WITH MY DLBCL

YOUR GUIDE TO TREATMENT WITH MINJUVI™



MINJUVI
tafasitamab for injection
200 mg/vial

For the following indication, MINJUVI™ has been approved *with conditions* (NOC/c). This means it has passed Health Canada's review and can be bought and sold in Canada, but the manufacturer has agreed to complete more studies to make sure the drug works the way it should. For more information, talk to your healthcare professional.

MINJUVI™ (tafasitamab) is indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, who are not eligible for autologous stem cell transplant (ASCT).



Information you'll find in this booklet

What is DLBCL?.....X

How does MINJUVI™ work?.....X

What will my treatment schedule be like?.....X

What are the possible side effects of treatment?.....X

Your MINJUVI™ treatment tracker.....X

Your personalized discussion guide.....X

The Incyte Solutions™ Support Program.....X

Tips for caregivers and loved ones.....X

Frequently asked questions (FAQ).....X

Glossary.....X



I'M ON A
MISSION
WITH MY DLBCL

MINJUVI™
tafasitamab for injection
200 mg/vial

Taking the next step in your DLBCL journey

Your doctor has prescribed treatment with MINJUVI™, which can be used to treat adult patients who have had their DLBCL return after other treatments or when other treatments did not work.


This booklet was designed to help you navigate the next phase of your journey with DLBCL. Use this as a guide to help you understand how MINJUVI™ works, how you can track your treatment, and more.

DRAFT

What is diffuse large B-cell lymphoma (DLBCL)?

DLBCL is the **most common type of non-Hodgkin lymphoma (NHL)** and is usually fast-growing. DLBCL specifically affects **mature B cells**, a type of white blood cell.

The lymphatic system



When DLBCL returns or stops responding to treatment

First-line treatment is the first treatment or series of treatments received.

Second-line (or subsequent) treatment is used when DLBCL has relapsed (returned) or become refractory (stopped responding) during a previous treatment. These treatment options are based on whether a blood stem cell transplant is part of the treatment plan.

One example of a blood stem cell transplant is an autologous stem cell transplant (ASCT), meaning your own blood stem cells are collected and later given back to you to help your body fight the cancer.



When DLBCL relapses or becomes refractory, doctors decide whether a transplant is an option based on many factors, such as:

- Any illnesses other than cancer
- How well your organs are working
- What you want
- Other relevant medical history

**After first-line treatment, your doctor
uses a variety of information to carefully
decide which option is best for you.**

DRAFT